Sanofi (NASDAQ:SNY) Shares Sold by Ledyard National Bank

Ledyard National Bank lessened its position in shares of Sanofi (NASDAQ:SNY) by 41.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,422 shares of the company’s stock after selling 9,684 shares during the quarter. Ledyard National Bank’s holdings in Sanofi were worth $647,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SNY. Franklin Resources Inc. boosted its position in Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after buying an additional 395,744 shares during the last quarter. Natixis Advisors LLC boosted its holdings in shares of Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after acquiring an additional 114,133 shares during the last quarter. Raymond James & Associates increased its stake in shares of Sanofi by 4.8% in the third quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock worth $162,479,000 after acquiring an additional 129,472 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Finally, DAVENPORT & Co LLC lifted its position in Sanofi by 40.7% during the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SNY has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $60.00.

Sanofi Trading Down 1.2 %

Shares of NASDAQ:SNY opened at $52.87 on Friday. The firm has a market capitalization of $134.18 billion, a price-to-earnings ratio of 21.23, a price-to-earnings-growth ratio of 1.26 and a beta of 0.57. The business’s 50 day moving average price is $49.62 and its 200-day moving average price is $52.35. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. On average, equities research analysts forecast that Sanofi will post 4.34 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.